Clinical translation of microbiome research
- PMID: 40217076
- DOI: 10.1038/s41591-025-03615-9
Clinical translation of microbiome research
Abstract
The landscape of clinical microbiome research has dramatically evolved over the past decade. By leveraging in vivo and in vitro experimentation, multiomic approaches and computational biology, we have uncovered mechanisms of action and microbial metrics of association and identified effective ways to modify the microbiome in many diseases and treatment modalities. This Review explores recent advances in the clinical application of microbiome research over the past 5 years, while acknowledging existing barriers and highlighting opportunities. We focus on the translation of microbiome research into clinical practice, spearheaded by Food and Drug Administration (FDA)-approved microbiome therapies for recurrent Clostridioides difficile infections and the emerging fields of microbiome-based diagnostics and therapeutics. We highlight key examples of studies demonstrating how microbiome mechanisms, metrics and modifiers can advance clinical practice. We also discuss forward-looking perspectives on key challenges and opportunities toward integrating microbiome data into routine clinical practice, precision medicine and personalized healthcare and nutrition.
© 2025. Springer Nature America, Inc.
Conflict of interest statement
Competing interests: J.A.G. is associated with Holobiome, BiomeSense, Bened Life and Sun Genomics. C.Y.C. is associated with Delve Bio and receives research support from Abbott Laboratories. P.S. is associated with Holobiome. E.E. and E.S. are associated with DayTwo. M.R.H. is associated with Seres Therapeutics. T.D.S. is associated with ZOE. S.V.L. is associated with Siolta Therapeutics. M.J.B. is associated with Seed Health, ProDermIQ and Elysium Health. M.B.A. is associated with Tiny Health. R.K. is associated with BiomeSense, GenCirq, DayTwo, Cybele and Biota.
Similar articles
-
Escape Velocity-the Launch of Microbiome Therapies.J Infect Dis. 2024 Jul 25;230(1):2-4. doi: 10.1093/infdis/jiae099. J Infect Dis. 2024. PMID: 39052747 Free PMC article.
-
[Microbiome: from pathophysiology to clinical application?].Dtsch Med Wochenschr. 2023 Nov;148(22):1419-1424. doi: 10.1055/a-1951-0063. Epub 2023 Nov 2. Dtsch Med Wochenschr. 2023. PMID: 37918425 Review. German.
-
Advances in Clostridioides difficile therapeutics.Expert Rev Anti Infect Ther. 2021 Sep;19(9):1067-1070. doi: 10.1080/14787210.2021.1874919. Epub 2021 Jan 17. Expert Rev Anti Infect Ther. 2021. PMID: 33427531 No abstract available.
-
Fecal Microbiota Transplantation: Indications, Methods, and Challenges.J Microbiol. 2024 Dec;62(12):1057-1074. doi: 10.1007/s12275-024-00184-3. Epub 2024 Nov 18. J Microbiol. 2024. PMID: 39557804 Review.
-
Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients.J Pediatric Infect Dis Soc. 2021 Nov 17;10(Supplement_3):S58-S63. doi: 10.1093/jpids/piab056. J Pediatric Infect Dis Soc. 2021. PMID: 34791396 Free PMC article. Review.
Cited by
-
Microbial proteases as emerging anti-inflammatory therapeutics: a comprehensive review.Arch Microbiol. 2025 Aug 19;207(9):229. doi: 10.1007/s00203-025-04409-w. Arch Microbiol. 2025. PMID: 40828296 Review.
-
Polymicrobial urine cultures: reconciling contamination with the urobiome while recognizing the pathogens.Front Cell Infect Microbiol. 2025 May 19;15:1562687. doi: 10.3389/fcimb.2025.1562687. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40458521 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous